bioRxiv Science⌕ Search

Biology subjects

Paatero, I.

Publications and source records attributed to Paatero, I..

At least 19 recordsLinked to original sources

SUMOylation is a Therapeutic Vulnerability in High-risk Neuroblastoma

Neuroblastoma (NB) is one of the most common solid malignancies in children, and high-risk patients have poor prognosis, underscoring the need for novel therapeutic agents. The small ubiquitin-like modifier (SUMO) is a reversible post-translational modification that regulates various protein functions, and the first-in-class SUMOylation inhibitor TAK-981 (subasumstat) is currently in clinical trials in adult cancer patients. However, the role of SUMOylation in NB pathogenesis remains poorly characterized. We show that SUMOylation-catalyzing enzymes, SAE1, SAE2, and UBE2I, are highly expressed in malignant neuroendocrine cells, and their expression correlate with poor survival in NB patients and associate with advanced stage, MYCN amplifications, and downregulation of late differentiation markers. The peripheral nervous system lineage and NB cell lines are highly sensitive to the CRISPR knockout of SAE1 and SAE2, suggesting SUMOylation as promising therapeutic target in NB. Accordingly, TAK-981-mediated inhibition of SUMOylation reduces growth of NB cells in both in vitro and in vivo models through induction of apoptosis and perturbation of differentiation-associated pathways. Sensitivity to SUMOylation inhibition is greatest in NB cells with low expression of favorable late neuroblast markers and is independent of MYCN amplification status. Moreover, TAK-981 is effective in combination with differentiation-inducing all-trans retinoic acid and the DNA methyltransferase inhibitor decitabine. Mechanistically, combination of TAK-981 and retinoic acid potently downregulates retinoic acid receptor alpha (RAR) expression, whereas inhibition of SUMOylation combined with decitabine induces a strong accumulation of DNA damage. Taken together, these findings establish SUMO pathway components as potential prognostic markers and SUMOylation as a therapeutic vulnerability in high-risk NB.

cancer biology↗

Scaffold protein SHANK3 regulates endothelial cell motility and tissue mechanics

SHANK3 is a multidomain scaffolding protein critical for neuronal function, which has been linked to neurodevelopmental disorders such as autism spectrum disorder. More recently, SHANK3 has been shown to play a role in cell survival and actin dynamics outside the nervous system. Here, we show that SHANK3 is widely expressed in endothelial cells across different tissues, where its role is not well understood. SHANK3 localised to endothelial cell-cell junctions in cultured endothelial cells, and its depletion compromised endothelial barrier function. SHANK silencing altered cell mechanics including elongated cell morphology, reduced cell-matrix traction forces and alteration of cell migration rate. It further triggered dynamic heterogeneity in endothelial monolayers, with regions of coordinated long-range migration interspersed with areas exhibiting only local velocity fluctuations, consistent with a transition toward more fluid-like tissue behaviour. This change in collective dynamics was accompanied by increased spheroid spreading and fusion, suggestive of altered tissue viscosity, and coincided with disrupted cell-cell junction morphology and mechanical forces in SHANK3-depleted cells. In vivo, SHANK3 depletion impaired endothelial cell migration, resulting in delayed sprouting of intersegmental vessels and disruption of the vascular network in zebrafish embryos. Furthermore, inducible endothelial-specific deletion of SHANK3 in postnatal mice impaired angiogenic sprouting and reduced vascular complexity in the developing retina. Overall, we demonstrate that SHANK3 plays a role in endothelial cell motility and tissue mechanics, with implications for vascular processes during development.

cell biology↗

Suppressing Bone Resorption and Promoting Mineralization with Tetracycline Derivatives

Osteoporosis is a progressive skeletal disorder characterized by decreased bone mass and an increased risk of fracture. Current treatments are limited by adverse effects and poor long-term compliance, necessitating alternative therapeutic approaches. Tetracycline (TC) derivatives, which are traditionally used as antibiotics, have shown promise in modulating bone remodeling. In this study, the effects of TC and three TC derivatives--oxytetracycline (OC), doxycycline (DC), and minocycline (MC)--on osteoclast and osteoblast activities were investigated using in vitro human cell models and in vivo zebrafish assays. All TC derivatives inhibited osteoclast differentiation and bone resorption, as shown by reductions in the number of TRAP-positive cells, resorption pit volume, and matrix metalloproteinase (MMP)-2/MMP-9 secretion. DC demonstrated the most potent inhibitory effects across all concentrations. Low to moderate concentrations of OC, DC, and MC promoted osteoblast proliferation and mineralization, whereas high doses inhibited these processes. Confocal imaging confirmed the accumulation of TC derivatives in mineralized bone nodules. Zebrafish studies revealed dose-dependent suppression of craniofacial bone development at higher concentrations. These findings highlight the dose dependent, dual effects of TC derivatives on bone cells (osteoblasts and osteoclasts) and underscore the potential of these agents as dual-function therapies for osteoporosis.

pharmacology and toxicology↗

Mitophagy promotes metabolic reprogramming to enhance keratinocyte migration via ANGPTL4 during wound healing

Mitochondrial function and quality control is emerging as a key regulator of keratinocyte migration in both wounding and non-wound healing contexts, yet the cellular mechanisms that support this process are incompletely understood. In this study, using single-cell RNA sequencing data of human wounded tissue we identified a distinct population of migrating keratinocytes marked by the high expression of the mitophagy regulator BNIP3 during the proliferative stage of wound healing. Pharmacological induction of mitophagy with Urolithin A accelerated keratinocyte migration in vitro as well as keratinocyte function and regeneration in aged zebrafish, whilst RNA sequencing of primary human keratinocytes revealed the transcriptional upregulation of ANGPTL4 in Urolithin-A treated cells. Mechanistically, Urolithin A increased metabolic switching to a more glycolytic phenotype, leading to AKTGSK3 pathway activity and FOSL1-mediated ANGPTL4 transcription, ultimately promoting keratinocyte migration through enhanced laminin-332 production. Overall, our findings uncover a novel role for mitophagy in promoting keratinocyte migration during wound repair, and demonstrate that pharmacologically enhancing mitophagy promotes regenerative epithelial responses by enhancing FOSL1-mediated ANGPTL4 signalling through the modulation of metabolic switching. These insights significantly expand the understanding of the role of mitophagy on keratinocyte function during wound healing, linking mitophagy to metabolic adaption in keratinocytes, and provide a mechanistic basis for targeting mitophagy or downstream genes in wound healing therapies.

developmental biology↗

Pharmacokinetics and efficacy of tank-water administered BRAF-inhibitor dabrafenib in a zebrafish model of BRAF-mutant melanoma

Zebrafish models are widely used to study the biology of BRAF-mutant melanoma. However, long-term treatment of adult fish with small molecule BRAF inhibitors is challenging, limiting the usefulness of this model to study treatment-induced effects in melanoma biology. In addition, pharmacokinetic studies on small molecule inhibitors in zebrafish that could inform rational dosing strategies, are largely lacking. Here, we have assessed the pharmacokinetics, metabolism and efficacy of continuous tank water -administered BRAF-inhibitor dabrafenib in adult zebrafish. Our results demonstrate that dabrafenib is quickly absorbed from the tank water, reaching efficacious plasma levels within one hour following treatment, but also shows fast elimination kinetics with a half-life of 1.6 hours. We could detect most of the human metabolites of dabrafenib in zebrafish, suggesting that dabrafenib metabolism in zebrafish follows a similar process as in humans. Continuous tank water -administered dabrafenib led to therapeutically relevant steady-state plasma levels that inhibited the BRAF-driven signaling and growth in zebrafish melanoma cells in vitro, and resulted in robust in vivo efficacy in a genetic zebrafish model of BRAF-mutant melanoma, with no apparent toxicity. Together, our results demonstrate that continuous tank water -administered dabrafenib provides a feasible, efficient, and well-tolerated dosing strategy to study treatment-related effects in zebrafish models of BRAF-mutant melanoma. We expect that tank water-administration may also facilitate the dosing of other small molecule inhibitors, especially those with short in vivo half-life in zebrafish. HighlightsO_LIPharmacokinetic analysis demonstrates fast absorption kinetics and short plasma half-life for tank water -administered dabrafenib in zebrafish C_LIO_LIDabrafenib is metabolized in zebrafish following a similar metabolic process as in humans C_LIO_LITank water -administered dabrafenib provides a feasible, efficient, and well-tolerated dosing strategy to study treatment-related effects in zebrafish models of BRAF-mutant melanoma C_LIO_LITank water-administration may facilitate dosing of small molecule inhibitors with short in vivo half-life in zebrafish C_LI

cancer biology↗

High resolution live imaging of tardigrade response to anoxia

Tardigrades are well-known for their ability to tolerate extreme environmental conditions such as heat, drought and lack of oxygen by undergoing cryptobiosis. The molecular responses to stress have been studied in detail, but the physiological and morphogenetic changes during cryptobiosis are less understood. We developed new live high-resolution fluorescence microscopy protocols to visualize the tardigrade response to lack of oxygen - anoxybiosis. High-resolution time-lapse imaging enabled analysis of cellular morphology and tracking of cell movements during anoxybiosis. These analyses revealed considerable changes in morphology, composition and movement of storage cells. Our observations and new imaging protocols can be used to study morphological and cellular response to stress in tardigrades.

cell biology↗

Heat stress sensitizes zebrafish embryos to neurological and cardiac toxicity.

Global warming increases the risk of dangerous heat waves, which may have deleterious effects on humans and wildlife. Here, we have utilized zebrafish embryos as a model to analyse heat stress and effect of chemical compounds on responses to heat stress. The temperature adaptation limit of zebrafish embryos was 37{degrees}C in behavioural test and 38{degrees}C in cardiac test. Polyaromatic hydrocarbon phenanthrene completely blocked the behavioural adaptation to heat stress. Interestingly, the cardiotoxic effects of lapatinib, phenanthrene and paclitaxel were induced by heat stress. Taken together, our data indicates that motility and cardiac function of zebrafish embryos can be utilized as a model to analyze modulatory effects of compounds on heat stress. HighlightsO_LIZebrafish embryos can be utilized as an in vivo model for acute heat stress C_LIO_LIPhenanthrene inhibited motility increase upon heat stress C_LIO_LICardiotoxicity of lapatinib, paclitaxel and phenanthrene was potentiated by heat stress C_LI

pharmacology and toxicology↗

Phosphoproteomic analysis reveals the diversity of signaling behind ErbB inhibitor-induced phenotypes

The impact of kinase inhibitors on the phosphoproteome has been rarely investigated at a whole organism level. Here we performed a phosphoproteomic analysis in embryonic zebrafish to identify the signaling pathways perturbed by ErbB receptor tyrosine kinase inhibitors at the organism level. The phosphorylation of proteins associated with the PI3K/Akt, p38 MAPK, Notch, Hippo/Yap and {beta}-catenin signaling pathways were differentially regulated by the ErbB inhibitors. Gene set enrichment analyses indicated differential neurological and myocardial phenotypes of different ErbB inhibitors. To assess the neurological and myocardial effects, motility and ventricle growth assays were performed on zebrafish embryos treated with the ErbB and downstream signaling pathway inhibitors. The treatment with the inhibitors targeting the PI3K/Akt, p38 MAPK, and Notch signaling pathways along with the ErbB inhibitors AG1478 and Lapatinib perturbed the overall movement and ventricle wall growth of zebrafish embryos. Taken together, these results indicate that inhibitors with the same primary targets can affect different signaling pathways while eliciting similar physiological phenotypes.

cell biology↗

JNK1 And Downstream Signalling Hubs Regulate Anxiety-Like Behaviours In A Zebrafish Larvae Phenotypic Screen

Current treatments for anxiety and depression show limited efficacy in many patients indicating that research into new underlying mechanisms is needed. Inhibition of JNK1 has been shown to evoke an anxiolytic-and antidepressant-like phenotype in mice however the downstream effectors that elicit these behavioural effects are unknown. Here we employ a zebrafish (D. Rerio) larvae behavioural assay to identify an antidepressant-/anxiolytic-like phenotype based on 2759 measured stereotypic responses to clinically proven antidepressant and anxiolytic (AA) drugs. Employing machine learning, we classify an AA phenotype from behavioural features measured during and after a startle battery in fish exposed to AA drugs (fluoxetine, imipramine, diazepam, lithium chloride, ketamine). We demonstrate that structurally independent JNK inhibitors replicate the AA classification with high accuracy, consistent with findings in mice. We go on to identify signalling hubs downstream from JNK1 by comparing phosphoproteome data from wildtype and Jnk1-/- mouse brains, and test these hubs as possible mediators of the AA phenotype in zebrafish larvae. Among these, we find that AKT, GSK-3, 14-3-3{zeta}/{varepsilon} and PKC{varepsilon}, when pharmacologically targeted, phenocopy clinically proven AA drugs. This assay shows promise as an early phase screening for compounds with anti-stress-axis/anxiolytic-like properties, and for mode of action analysis.

pharmacology and toxicology↗

TLNRD1 is a CCM complex component and regulates endothelial barrier integrity

We previously identified talin rod domain-containing protein 1 (TLNRD1) as a potent actin-bundling protein in vitro. Here, we report that TLNRD1 is primarily expressed in the vasculature in vivo and that its depletion leads to vascular abnormalities in vivo and loss of barrier integrity in cultured endothelial cells. We demonstrate that TLNRD1 is a component of the cerebral cavernous malformations (CCM) complex through its direct, high-affinity interaction with CCM2. Modeling and functional testing of TLNRD1 and CCM2 mutants reveal that their interaction is mediated by a hydrophobic C-terminal helix in CCM2 that attaches to a hydrophobic groove on the 4-helix domain of TLNRD1. Disruption of this binding interface leads to CCM2 and TLNRD1 accumulation in the nucleus and actin fibers. Notably, a CCM2 pathogenic mutation linked to vascular dementia in patients maps to the interface and disrupts the interaction. Our findings indicate that CCM2 controls TLNRD1 localization to the cytoplasm and inhibits its actin-bundling activity. Based on these results, we propose a new pathway by which the CCM complex modulates the actin cytoskeleton and vascular integrity by controlling TLNRD1 bundling activity.

cell biology↗

Transcriptional landscape of DTP-DTEP transition reveals DUSP6 as a driver of HER2 inhibitor tolerance via Neuregulin/HER3 axis

The mechanisms promoting re-growth of dormant cancer cells under continuous tyrosine kinase inhibitor (TKI) therapy are poorly understood. Here we present transcriptional profiling of HER2+ breast cancer cells treated continuously with HER2 TKI (HER2i) therapy for 9 months. The data reveals specific gene regulatory programs associated with transition from dormant drug tolerant persister cells (DTPs) to proliferating DTEP (drug tolerant expanding persister) cells and eventually long-term resistance. Focusing on yet poorly understood phosphatases as determinants of therapy tolerance, expression of dual-specificity phosphatase DUSP6 was found inhibited in DTPs, but strongly induced upon re-growth of DTEPs. DUSP6 overexpression conferred apoptosis resistance whereas its pharmacological blockade prevented DTEP development under HER2i therapy. The DUSP6-driven HER2i tolerance was mediated by activation of neuregulin-HER3 axis, and consistent with the role of HER3 in widespread therapy tolerance, DUSP6 targeting also synergized with clinically used HER2i combination therapies. In vivo, pharmacological DUSP6 targeting induced synthetic lethal effect with HER2i in independent tumor models, and its genetic targeting reduced tumor growth in orthotopic brain metastasis model. Collectively this work provides first transcriptional landscape of DTP-DTEP transition under TKI therapy, and identify DUSP6 as a novel candidate therapy target to overcome widespread HER3-driven therapy resistance.

cancer biology↗

Effect of caldesmon mutations in the development of zebrafish embryos.

Cancer is a profound medical concern and better treatments are needed for cancer patients. Therefore, new cancer targets are constantly being studied. These targets need not only be relevant for cancer progression, but their modulation needs to be tolerated reasonably well by the host. Caldesmon is one of these proposed novel targets for cancer therapy. Therefore, we analysed effects of caldesmon mutations in normal development using genetically modified zebrafish embryos. We analysed mutations in both zebrafish caldesmon genes, cald1a and cald1b and analysed effects of either mutation alone or as in combination in double homozygous embryos using molecular, morphological and functional analyses. The effects of caldesmon mutations were mild and the gross development of zebrafish embryos was normal. The caldesmon mutant embryos had, however, alterations in response to light-stimulus in behavioral assays. Taken together, the effects of caldesmon mutations in the development of zebrafish embryos were reasonably well tolerated and did not indicate significant concerns for caldesmon being a potential target for cancer therapy.

developmental biology↗

Database of recurrent mutations (DORM), a web tool to browse recurrent mutations in cancers

Advances in sequencing technologies have facilitated the genetic characterization of large numbers of clinical cancer samples, leading to accumulation of extensive amounts of data. While potentially very useful for directing research and for clinical decision making, the increasing quantity of data generates challenges in its optimal management, and translation to informing clinical and research questions. Here, we present Database Of Recurrent Mutations (DORM), a database listing recurrent mutations (tissue-agnostic population frequency > 1) identified from cancer samples analyzed with whole genome or whole exome sequencing. The DORM database is a fast and feature-rich database supporting searching for several proteins, amino acid substitutions as well as queries using regular expressions.

bioinformatics↗

STAT5b is a key effector of NRG-1/ERBB4-mediated cardiomyocyte growth

The growth factor neuregulin-1 (NRG-1) regulates hypertrophic and hyperplastic myocardial growth and is currently under clinical investigation as a treatment for heart failure. We have previously demonstrated that an isoform of the NRG-1 receptor ERBB4 (ERBB4 JM-b) expressed in cardiomyocytes selectively regulates the activation of STAT5b. To explore the role of STAT5b in NRG-1/EBBB4 mediated cardiomyocyte growth, several in vitro and in vivo models were utilized. The downregulation of NRG-1/ERBB4 signaling consistently reduced STAT5b activation and transcription of STAT5b target genes Igf1, Myc and Cdkn1a in murine in vitro and in vivo models of myocardial growth. Stat5b knock-down in primary cardiomyocytes ablated NRG-1-induced cardiomyocyte hypertrophy. Stat5b was activated during NRG-1-induced hyperplastic myocardial growth and chemical inhibition of the Nrg-1/Erbb4 pathway led to the loss of myocardial growth and Stat5 activation in zebrafish embryos. Moreover, CRISPR/Cas9-mediated knock-down of stat5b in zebrafish embryos resulted in reduced myocardial growth and heart failure as indicated by reduced ventricular ejection fraction. Dynamin-2 was discovered to control the cell surface localization of ERBB4 and the chemical inhibition of dynamin-2 downregulated NRG-1/ERBB4/STAT5b signaling in models of hypertrophic and hyperplastic myocardial growth. Finally, the activation of the NRG-1/ERBB4/STAT5b signaling pathway was explored in clinical samples representing pathological cardiac hypertrophy. The NRG-1/ERBB4/STAT5b signaling pathway was differentially regulated both at the mRNA and protein levels in the myocardium of patients with pathological cardiac hypertrophy as compared to myocardium of control subjects. These results establish the role for STAT5b, and dynamin-2 in NRG-1/ERBB4-mediated myocardial growth.

cell biology↗

Reduced wound healing and angiogenesis in aged zebrafish and turquoise killifish.

Impaired wound healing is associated with aging and has significant effects on human health on an individual level, but also the whole health care sector. Deficient angiogenesis appears to be involved in the process, but the underlying biology is still poorly understood. This is at least partially being explained by complexity and costs in using mammalian aging models. To understand aging-related vascular biology of impaired wound healing, we have utilized zebrafish and turquoise killifish fin regeneration models. The regeneration of caudal fin after resection was significantly reduced in old individuals in both species. Age-related changes in angiogenesis, vascular density and expression levels of angiogenesis biomarker VEGF-A were observed. Furthermore, anti-angiogenic drug, vascular endothelial growth factor receptor blocking inhibitor SU5416 reduced regeneration indicating a key role for angiogenesis in the regeneration of aging caudal fin despite aging-related changes in vasculature. Taken together, our data indicates that these fish models are suitable for studying aging-related decline in wound healing and associated alterations in aging vasculature.

developmental biology↗

Myosin-X-dependent assembly of the extracellular matrix limits breast cancer invasion

Ductal carcinoma in situ (DCIS) is a pre-invasive stage of breast cancer, where the tumor is encapsulated by a basement membrane (BM). At the invasive phase, the BM barrier is compromised enabling tumor cells to escape into the surrounding stroma. The molecular mechanisms that establish and maintain an epithelial BM barrier in vivo are poorly understood. Myosin-X (MYO10) is a filopodia-inducing motor protein implicated in metastasis and poor clinical outcome in patients with invasive breast cancer (IBC). We compared MYO10 expression in patient-matched normal breast tissue and DCIS lesions and found elevated MYO10 expression in DCIS samples, suggesting that MYO10 might facilitate the transition from DCIS to IBC. Indeed, MYO10 promoted the formation of filopodia and cell invasion in vitro and positively regulated the dissemination of individual cancer cells from IBC lesions in vivo. However, MYO10-depleted DCIS xenografts were, unexpectedly, more invasive. In these xenografts, MYO10 depletion compromised BM formation around the lesions resulting in poorly defined tumor borders and increased cancer cell dispersal into the surrounding stroma. Moreover, MYO10-depleted tumors showed increased EMT-marker-positive cells, specifically at the tumor periphery. We also observed cancer spheroids undergoing rotational motion and recruiting BM components in a filopodia-dependent manner to generate a near-continuous extracellular matrix boundary. Taken together, our data identify a protective role for MYO10 in early-stage breast cancer, where MYO10-dependent tumor cell protrusions support BM assembly at the tumor-stroma interface to limit cancer progression, and a pro-invasive role that facilitates cancer cell dissemination at later stages. O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=123 SRC="FIGDIR/small/464987v2_ufig1.gif" ALT="Figure 1"> View larger version (28K): org.highwire.dtl.DTLVardef@d90a4eorg.highwire.dtl.DTLVardef@133ba9borg.highwire.dtl.DTLVardef@1204a05org.highwire.dtl.DTLVardef@dba254_HPS_FORMAT_FIGEXP M_FIG C_FIG Highlights- Filopodia sculpt the tumor-proximal stroma in pre-invasive ductal carcinoma in situ (DCIS). - Filopodia-dependent basement membrane (BM) assembly limits invasive transition of DCIS-like tumors in vivo. - Loss of MYO10-dependent filopodia impairs BM assembly and induces an EMT-like phenotype at the tumor-stroma interface in vivo. - MYO10 filopodia are anti-invasive in DCIS but facilitate dissemination in invasive breast cancer.

cell biology↗

Conformational dynamics regulate SHANK3 actin and Rap1 binding

Actin-rich cellular protrusions direct versatile biological processes from cancer cell invasion to dendritic spine development. The stability, morphology and specific biological function of these protrusions are regulated by crosstalk between three main signaling axes: integrins, actin regulators and small GTPases. SHANK3 is a multifunctional scaffold protein, interacting with several actin-binding proteins, and a well-established autism risk gene. Recently, SHANK3 was demonstrated to sequester integrin-activating small GTPases Rap1 and R-Ras to inhibit integrin activity via its N-terminal SPN domain. Here, we demonstrate that SHANK3 interacts directly with actin using its SPN domain. Actin binding can be inhibited by an intramolecular closed conformation of SHANK3, where the adjacent ARR domain covers the actin-binding interface of the SPN domain. Actin and Rap1 compete with each other for binding to SHANK3 and loss of SHANK3-actin binding augments inhibition of Rap1-mediated integrin activity. This dynamic crosstalk has functional implications for filopodia formation in cancer cells, dendritic spine morphology in neurons and autism-linked phenotypes in vivo.

cell biology↗

Control of dynamic cell behaviors during angiogenesis and anastomosis by Rasip 1

Organ morphogenesis is driven by a wealth of tightly orchestrated cellular behaviors, which ensure proper organ assembly and function. Many of these cell activities involve cell-cell interactions and remodeling of the F-actin cytoskeleton. Here, we analyze the requirement for Rasip1 (Ras-interacting protein 1), an endothelial-specific regulator of junctional dynamics, during blood vessel formation. Phenotype analysis of rasip1 mutants in zebrafish embryos reveal distinct requirements for Rasip1 during sprouting angiogenesis, vascular anastomosis and lumen formation. During angiogenic sprouting, Rasip1 is required for efficient cell pairing, which is essential for multicellular tube formation. High-resolution time-lapse analyses show that these cell pairing defects are caused by a destabilization of tricellular junctions suggesting that tri-cellular junctions may serve as a counterfort to tether sprouting endothelial cells during morphogenetic cell rearrangements. During anastomosis, Rasip1 is required to establish a stable apical membrane compartment; rasip1 mutants display ectopic, reticulated junctions and the apical compartment is frequently collapsed. Loss of Ccm1 and Heg1 function leads to junctional defects similar to those seen in rasip1 mutants. Analysis of radil-b single and rasip1/radil-b double mutants reveal distinct and overlapping functions of both proteins. While Rasip1 and Radil-b have similar functions during angiogenic sprouting, the junction formation during anastomosis may primarily depend on Rasip1.

developmental biology↗